Company intelligence / Profile preview

Karius

Redwood City, California, United Stateskariusdx.com ↗

Ownership: Private
Employees: ~190
Development stage: Commercial

Overview

The Karius Test® provides rapid, non-invasive detection of over 1000 pathogens from a single blood sample using next-generation sequencing of microbial cell-free DNA. It has received FDA Breakthrough Device Designation and has demonstrated improved diagnosis/management of pneumonia in immunocompromised patients. Clinical studies show utility for faster diagnosis compared to standard-of-care methods.

Therapeutic areas: Infectious Diseases
Modalities: Diagnostic test (liquid biopsy)Genomics-based diagnosticsArtificial intelligence-enabled diagnostics
Industry: Molecular Diagnostics

Drug pipeline

1 asset

Karius Test

Commercial

Indications: Infectious diseases

Partnerships

eGenesis (collaboration on xenotransplantation infection monitoring)

Beyond the preview

Go deeper on Karius.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Karius.

Explore the full profile